The Danish biopharmaceutical company, ALK, announced on May 18 in Madrid its plans for expansion in Spain, which include significant investments and new projects at the facilities it has in the capital. "The ALK endeavor in Spain and, more specifically, in Madrid involves employment, investment and recognition of qualified, well-executed work," Carsten Hellmann, the CEO and President of the Group said.
Firstly, ALK announced its backing of Madrid to centralize the distribution of all products the company markets under its brand in over 40 countries. As Hellmann explained, "ALK-Abelló has demonstrated it is capable of centralizing the management of all ALK processes, guaranteeing maximum quality and safety in production systems."
As a consequence of this decision, Madrid will be leading large ALK projects. "These decisions make Madrid the international logistics center for the distribution of products to more than 40 countries. Furthermore, the plant in Madrid will produce a new line of personalized subcutaneous treatments for allergies," Claudio Fusari, the Director-General of ALK-Abelló, explained.
This expansion plan also brings with it the expansion of the ALK facilities in Madrid. The administrative activities have been transferred to modern offices covering 900 square meters a short distance from the rest of the facilities.
Furthermore, the Information Technology Department has been relocated and centralized in Madrid, adding twenty new employees in high-ranking roles for the development, support, training and validation of systems. In total, according to the estimations of Fusari, at this new Information Technology HUB "more than a hundred new job posts will be created, including technical, scientific and commercial roles."
Another department moving to Spain from Denmark is Quality Control. Its transfer has already involved the creation of twenty jobs, with another fifteen to follow. ALK has plans to invest a total of €3 million in these laboratories, which have new, high-quality equipment in an area of 500 square meters.
Trust with history
The facilities of ALK-Abelló, which is the ALK subsidiary in Spain, were expanded in 2015 to house the international logistics center for labeling, packaging and shipping, and the production center for allergenic extracts via cutaneous testing, as Fusari recalls, adding: "In June this year the production plant for the Jext adrenaline auto-injector was opened with an investment at the local plant of €6 million and an increase in the workforce to the tune of 35 jobs, that may rise to 70 in the coming years. Today, this plant supplies the device to the majority of European markets, China and South Korea."
ALK is the leader in the immunotherapy sector specifically against allergic diseases with 41% of the world market share. ALK-Abelló currently has 240 employees in Madrid, shared across its Production, R&D, Marketing and Sales facilities.
The Danish company's decision to back Spain will also see it stage its Spanish market launch of the medication Acarizax.
Last updated: 30|06|2017